SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine (STO:AEROB):
With reference to Chapter 4 Section 9 in ”lagen (1991:980) om handel med finansiella instrument” it’s hereby announced that through the subscription by exercise of options in Aerocrine the number of shares and votes in Aerocrine has increased during May 2012 as specified in the table below.
Number of shares and votes
June 1, 2012
144 583 278
Increase
38 642
June 29, 2012
144 621 920
Solna June 29, 2012
Aerocrine AB (publ.)
About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:01 a.m. on June 29, 2012.
This information was brought to you by Cision http://www.cisionwire.com
Contacts
Michael Colérus, CFO
+46 8 629 07 85
